Flex Biomedical, Inc.
Sal Braico
CEO

Flex Biomedical is developing innovative treatments for orthopedic diseases. The company’s lead product, the Flex Polymer™, is a synthetic polymer viscosupplement designed to treat osteoarthritis, an incurable, debilitating disease that affects 27 million people in the United States and 200 million people worldwide. The Flex Polymer is a superior lubricant, cushion, and has an extended joint residence time.